指南与共识系统性红斑狼疮

2025 ACR系统性红斑狼疮治疗指南

2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus.
指南 / 共识 · Arthritis Rheumatol · 2025-11-04

该指南针对非肾脏系统性红斑狼疮(SLE)的治疗与管理,采用PICO格式构建临床问题,通过系统文献综述和GRADE方法评估证据质量并形成推荐,投票专家组对每条推荐的方向和强度达成≥70%共识。推荐强调统一使用羟氯喹、限制糖皮质激素使用时长以及早期引入传统和/或生物免疫抑制疗法,以控制SLE炎症、减少疾病相关发病率和死亡率并最小化药物毒性。

要点

  • 推荐统一使用羟氯喹治疗SLE。
  • 限制糖皮质激素的使用时长。
  • 早期引入传统和/或生物免疫抑制疗法以控制炎症。

核心结论

  • 该指南为SLE治疗与管理提供方向性推荐,为临床医患共同决策提供基础,推荐不应被用于限制或拒绝治疗获取。

研究设计与样本

  • 指南由美国风湿病学会(ACR)制定,采用PICO格式构建临床问题,系统文献综述和GRADE方法评估证据质量并形成推荐,投票专家组达成≥70%共识。

主要发现

  • 推荐强调统一使用羟氯喹、限制糖皮质激素使用时长、早期引入传统和/或生物免疫抑制疗法,以控制SLE炎症(缓解或低疾病活动度)、减少发病率和死亡率并最小化药物毒性。

关键数值与推荐

  • 每条推荐需投票专家组达成≥70%共识(方向和强度)。

临床怎么用

  • 推荐适用于儿童和成人SLE患者,治疗决策应考虑每位患者的独特临床情况和偏好。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To provide evidence-based and expert guidance for the treatment and management of non-renal systemic lupus erythematosus (SLE); treatment and management of lupus nephritis are addressed in a separate guideline. METHODS: Clinical questions for treatment and management of SLE were developed in the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were developed for each PICO question, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess evidence quality and formulate recommendations. The Voting Panel achieved a consensus of ≥70% agreement on the direction (for or against) and strength (strong or conditional) of each recommendation. RESULTS: We present recommendations and ungraded, consensus-based good practice statements for the treatment and management of SLE that are applicable to pediatric and adult patients. Recommendations emphasize uniform treatment with hydroxychloroquine, limiting duration of glucocorticoid use, and early introduction of conventional and/or biologic immunosuppressive therapies to achieve and maintain control of SLE inflammation (remission or a low level of disease activity), reduce SLE-related morbidity and mortality, and minimize medication-related toxicities. CONCLUSION: This guideline presents direction regarding treatment and management of SLE and provides a foundation for well-informed, shared clinician-patient decision-making. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each person with SLE.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Sammaritano LR, Askanase A, Bermas BL, et al. 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus. Arthritis Rheumatol. 2025. PMID: 41187097. doi:10.1002/art.43452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。